Human ATP2B4/ATP2B2/MXRA1 ORF/cDNA clone-Lentivirus plasmid (NM_001684)

Cat. No.: pGMLP001604
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human ATP2B4/ATP2B2/MXRA1 Lentiviral expression plasmid for ATP2B4 lentivirus packaging, ATP2B4 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to ATP2B4/ATP2B2 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1747.2
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP001604
Gene Name ATP2B4
Accession Number NM_001684
Gene ID 493
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 3618 bp
Gene Alias ATP2B2,MXRA1,PMCA4,PMCA4b,PMCA4x
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGACGAACCCATCAGACCGTGTCTTGCCTGCCAACTCGATGGCCGAGAGCCGTGAAGGGGACTTTGGCTGCACAGTAATGGAACTGAGGAAGCTCATGGAGCTGCGTTCAAGGGATGCACTGACCCAGATTAATGTCCACTATGGAGGTGTACAGAATCTCTGCAGTAGACTGAAAACCTCCCCTGTGGAAGGTCTGTCTGGGAACCCTGCAGATCTGGAGAAACGTAGGCAGGTGTTTGGACACAACGTGATCCCCCCCAAAAAGCCCAAGACTTTCTTAGAATTAGTGTGGGAAGCTCTTCAAGATGTCACGCTTATCATCCTGGAGATTGCAGCCATCATCTCCCTGGTCCTGTCCTTTTATCGCCCTGCTGGTGAAGAAAATGAACTGTGTGGTCAAGTCGCAACTACCCCAGAAGATGAAAATGAGGCACAAGCTGGCTGGATTGAGGGGGCAGCCATCCTTTTCTCAGTGATCATCGTGGTGTTAGTGACTGCCTTTAATGATTGGAGCAAAGAGAAGCAATTCCGGGGGCTGCAGTGCCGCATTGAACAGGAGCAAAAGTTCTCCATCATCCGAAACGGTCAACTCATCCAGCTCCCTGTGGCTGAGATTGTGGTTGGTGATATTGCCCAAGTCAAATACGGTGATCTGCTGCCTGCAGATGGAATCCTGATCCAAGGGAATGATCTGAAGATTGATGAGAGCTCTCTGACAGGGGAATCTGACCATGTCAAGAAGTCCCTGGACAAAGACCCCATGTTGCTCTCAGGGACCCATGTCATGGAAGGTTCTGGCCGGATGGTGGTGACAGCTGTTGGTGTCAACTCTCAGACTGGAATCATCCTTACTCTCTTGGGGGTCAATGAGGATGACGAAGGGGAGAAAAAGAAGAAAGGTAAAAAACAAGGAGTCCCTGAAAATCGCAACAAAGCAAAGACCCAAGACGGAGTGGCCCTGGAAATCCAGCCACTCAACAGCCAGGAGGGAATCGACAATGAGGAAAAGGACAAGAAGGCAGTCAAGGTGCCTAAAAAGGAGAAGTCAGTGCTGCAGGGCAAGCTGACTCGCCTGGCTGTTCAGATTGGGAAAGCCGGTCTGCTCATGTCTGCTCTCACGGTTTTCATCCTGATTCTATACTTTGTGATTGACAACTTTGTGATAAATCGCAGACCATGGCTCCCTGAGTGTACTCCCATCTACATCCAGTACTTTGTCAAGTTCTTCATCATCGGCATCACTGTACTGGTGGTGGCTGTGCCAGAGGGGCTGCCTCTGGCTGTCACCATCTCACTGGCCTACTCTGTGAAGAAAATGATGAAAGACAATAACCTAGTACGGCACTTGGATGCTTGTGAGACCATGGGCAACGCCACCGCCATCTGCTCTGATAAGACAGGCACGTTGACCATGAACCGCATGACTGTGGTACAAGCTTATATTGGGGGCATCCATTACCGTCAAATCCCAAGCCCTGATGTCTTCCTGCCCAAAGTCCTGGACCTCATTGTCAATGGCATTTCTATCAACAGTGCTTATACCTCCAAGATTCTGCCTCCAGAGAAGGAGGGAGGCCTGCCTCGGCAGGTGGGCAACAAGACCGAGTGTGCTCTGCTAGGCTTTGTCACAGATCTGAAGCAGGATTATCAGGCTGTGCGTAATGAAGTGCCCGAGGAGAAGCTCTACAAGGTGTACACCTTTAACTCAGTGCGCAAGTCAATGAGCACCGTCATCAGGAATCCCAACGGTGGCTTCCGTATGTACAGCAAGGGCGCCTCTGAGATCATCTTGCGCAAGTGTAATCGAATCCTGGACCGGAAAGGGGAAGCAGTGCCATTCAAGAATAAAGACAGAGATGATATGGTACGCACTGTCATCGAGCCCATGGCCTGTGATGGACTCCGGACTATCTGCATAGCTTACCGGGACTTCGATGACACAGAGCCCTCTTGGGACAATGAGAATGAGATCCTCACCGAACTGACCTGTATCGCGGTGGTGGGCATTGAGGACCCTGTGCGCCCAGAGGTGCCAGATGCTATTGCCAAATGCAAACAAGCTGGCATTACTGTCAGAATGGTGACAGGTGACAACATCAACACAGCCCGGGCCATTGCCACCAAATGTGGCATTCTGACACCTGGGGATGACTTCCTGTGCTTAGAAGGCAAAGAATTCAACCGGCTCATCCGCAACGAGAAAGGCGAGGTAGAGCAAGAAAAGCTGGACAAGATCTGGCCTAAGCTTCGGGTCCTGGCGCGATCTTCTCCCACTGACAAGCACACCCTGGTGAAAGGCATAATTGACAGCACTGTTGGGGAACACCGGCAGGTCGTGGCTGTCACTGGTGATGGCACAAATGACGGGCCTGCTCTGAAGAAAGCGGATGTTGGTTTTGCCATGGGCATCGCAGGCACAGATGTAGCAAAGGAGGCTTCAGACATCATCCTAACAGATGACAACTTCACCAGCATTGTGAAGGCAGTGATGTGGGGACGAAATGTCTATGACAGCATCTCCAAGTTCCTGCAGTTCCAGCTCACTGTCAATGTGGTGGCCGTGATTGTAGCCTTCACTGGAGCCTGTATCACTCAGGATTCCCCATTGAAAGCTGTGCAGATGTTGTGGGTTAATCTGATCATGGACACTTTTGCTTCATTGGCCCTGGCCACAGAGCCCCCTACGGAATCTCTGTTGAAGCGGCGCCCCTATGGCCGAAATAAGCCTCTGATCTCACGCACTATGATGAAGAACATCTTGGGCCATGCATTCTATCAGCTCATTGTCATCTTTATCCTTGTCTTTGCGGGTGAGAAATTCTTTGATATTGATAGTGGGAGGAAGGCACCTCTACATTCACCACCCAGCCAGCACTATACCATTGTTTTTAACACCTTCGTGCTGATGCAGCTCTTCAATGAAATCAACTCCCGAAAGATCCATGGAGAGAAGAACGTCTTTTCAGGCATCTACCGCAACATTATCTTCTGCTCTGTAGTCTTGGGCACATTCATCTGCCAGATTTTCATCGTGGAATTTGGGGGTAAACCCTTCAGTTGTACAAGCCTCAGCCTGTCTCAGTGGCTGTGGTGTCTCTTCATTGGGATTGGAGAACTTCTGTGGGGCCAGTTCATCTCCGCAATACCTACCCGATCCCTGAAGTTCCTGAAGGAGGCTGGGCATGGCACCACCAAAGAGGAGATCACCAAGGATGCCGAGGGACTGGATGAGATTGACCATGCTGAGATGGAGCTGCGCCGAGGCCAGATCCTCTGGTTCCGGGGCCTGAACCGTATCCAGACTCAGATCAAAGTGGTCAAAGCGTTCCATAGTTCCCTCCACGAAAGCATTCAGAAACCCTACAACCAAAAGTCCATCCACAGCTTCATGACCCACCCTGAATTCGCCATAGAGGAGGAGTTGCCACGAACACCACTCCTGGATGAGGAAGAGGAGGAAAATCCTGACAAGGCTTCTAAGTTTGGGACTAGGGTGCTCCTGTTGGATGGTGAGGTCACTCCATATGCCAATACAAACAACAATGCGGTGGATTGCAACCAAGTGCAGCTCCCCCAGTCGGACAGCTCTCTACAGAGCCTAGAGACATCAGTTTGA
ORF Protein Sequence MTNPSDRVLPANSMAESREGDFGCTVMELRKLMELRSRDALTQINVHYGGVQNLCSRLKTSPVEGLSGNPADLEKRRQVFGHNVIPPKKPKTFLELVWEALQDVTLIILEIAAIISLVLSFYRPAGEENELCGQVATTPEDENEAQAGWIEGAAILFSVIIVVLVTAFNDWSKEKQFRGLQCRIEQEQKFSIIRNGQLIQLPVAEIVVGDIAQVKYGDLLPADGILIQGNDLKIDESSLTGESDHVKKSLDKDPMLLSGTHVMEGSGRMVVTAVGVNSQTGIILTLLGVNEDDEGEKKKKGKKQGVPENRNKAKTQDGVALEIQPLNSQEGIDNEEKDKKAVKVPKKEKSVLQGKLTRLAVQIGKAGLLMSALTVFILILYFVIDNFVINRRPWLPECTPIYIQYFVKFFIIGITVLVVAVPEGLPLAVTISLAYSVKKMMKDNNLVRHLDACETMGNATAICSDKTGTLTMNRMTVVQAYIGGIHYRQIPSPDVFLPKVLDLIVNGISINSAYTSKILPPEKEGGLPRQVGNKTECALLGFVTDLKQDYQAVRNEVPEEKLYKVYTFNSVRKSMSTVIRNPNGGFRMYSKGASEIILRKCNRILDRKGEAVPFKNKDRDDMVRTVIEPMACDGLRTICIAYRDFDDTEPSWDNENEILTELTCIAVVGIEDPVRPEVPDAIAKCKQAGITVRMVTGDNINTARAIATKCGILTPGDDFLCLEGKEFNRLIRNEKGEVEQEKLDKIWPKLRVLARSSPTDKHTLVKGIIDSTVGEHRQVVAVTGDGTNDGPALKKADVGFAMGIAGTDVAKEASDIILTDDNFTSIVKAVMWGRNVYDSISKFLQFQLTVNVVAVIVAFTGACITQDSPLKAVQMLWVNLIMDTFASLALATEPPTESLLKRRPYGRNKPLISRTMMKNILGHAFYQLIVIFILVFAGEKFFDIDSGRKAPLHSPPSQHYTIVFNTFVLMQLFNEINSRKIHGEKNVFSGIYRNIIFCSVVLGTFICQIFIVEFGGKPFSCTSLSLSQWLWCLFIGIGELLWGQFISAIPTRSLKFLKEAGHGTTKEEITKDAEGLDEIDHAEMELRRGQILWFRGLNRIQTQIKVVKAFHSSLHESIQKPYNQKSIHSFMTHPEFAIEEELPRTPLLDEEEEENPDKASKFGTRVLLLDGEVTPYANTNNNAVDCNQVQLPQSDSSLQSLETSV

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP0106-Ab Anti-AT2B4/ ATP2B4/ ATP2B2 monoclonal antibody
    Target Antigen GM-Tg-g-MP0106-Ag ATP2B4 VLP (virus-like particle)
    ORF Viral Vector pGMLP001604 Human ATP2B4 Lentivirus plasmid
    ORF Viral Vector vGMLP001604 Human ATP2B4 Lentivirus particle


    Target information

    Target ID GM-MP0106
    Target Name ATP2B4
    Gene ID 493, 381290, 574317, 29600, 101101538, 403731, 282146, 100049920
    Gene Symbol and Synonyms ATP2B1,ATP2B2,ATP2B4,MXRA1,PMCA4,PMCA4b,PMCA4x
    Uniprot Accession P23634
    Uniprot Entry Name AT2B4_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000058668
    Target Classification Not Available

    The protein encoded by this gene belongs to the family of P-type primary ion transport ATPases characterized by the formation of an aspartyl phosphate intermediate during the reaction cycle. These enzymes remove bivalent calcium ions from eukaryotic cells against very large concentration gradients and play a critical role in intracellular calcium homeostasis. The mammalian plasma membrane calcium ATPase isoforms are encoded by at least four separate genes and the diversity of these enzymes is further increased by alternative splicing of transcripts. The expression of different isoforms and splice variants is regulated in a developmental, tissue- and cell type-specific manner, suggesting that these pumps are functionally adapted to the physiological needs of particular cells and tissues. This gene encodes the plasma membrane calcium ATPase isoform 4. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.